VIDEO: Patient-reported outcomes from OlympiA presented at SABCS
Susan M. Domchek, MD, executive director of the Basser Center for BRCA and the director of the MacDonald Cancer Risk Evaluation Center at Penn Medicine, spoke with Healio about updated results from the OlympiaA trial.
Findings on patient-reported quality-of-life outcomes among patients with BRCA1/2 mutations and high risk, early-stage breast cancer who received olaparib [Lynparza; AstraZeneca, Merck] compared with those who received placebo were presented at this year’s San Antonio Breast Cancer Symposium.
“The most important things here are that there are some small differences in patient-reported outcomes, but fortunately, they’re pretty small,” Domchek said, adding that “it really suggests that — with appropriate symptom management, support and dose reductions — that individuals can do quite well with olaparib for a year.”
Collapse
Ganz PA, et al. Abstract GS4-09. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
Read more about